

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETARY OF THE SENATE  
02 FEB 14 PM 4:04

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Bennett, Turner & Coleman, LLP			
2. Address <input type="checkbox"/> Check if different than previously reported 1900 K Street NW, Suite 750 Washington, DC 20006			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name Albert Cacoza		Telephone 202-833-4500	E-mail (optional) _____
5. Senate ID # 53298-19			6. House ID # 3497601
7. Client Name <input type="checkbox"/> Self Novartis Pharmaceuticals Corporation			

**TYPE OF REPORT** 8. Year 2001 Midyear (January 1-June 30)  OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_

11. No Lobbying

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>20,000</u> Income (nearest \$20,000)	<b>EXPENSES</b> relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 6032 Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code

Signature \_\_\_\_\_

Printed Name and Title Terry S. Coleman, Partner



Registrant Name Bennett, Turner & Coleman, LLP Client Name Novartis Pharmaceuticals Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare reimbursement for oral anti-cancer therapies  
H.R. 1624; S. 913

17. House(s) of Congress and Federal agencies contacted

Check if None

U.S. House of Representatives  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sam Turner, Partner	
Elizabeth Goss, Partner	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

To the degree that public policies, either laws or regulations, commercially benefit Novartis Pharmaceutical Corporation, so too Novartis AG will benefit. Novartis AG is the parent company of Novartis Pharmaceutical Corporation and the parent benefits in the commercial success of its subsidiary.

Signature Terry Coleman

Date February 8, 2002

Printed Name and Title Terry S. Coleman, Partner

